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Abstract: Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of potentially
devastating primary skin malignancies. Despite decades of intense research efforts, the pathogenesis
is still not fully understood. In the early stages, both clinical and histopathological diagnosis is often
difficult due to the ability of CTCL to masquerade as benign skin inflammatory dermatoses. Due to a
lack of reliable biomarkers, it is also difficult to predict which patients will respond to therapy or
progress towards severe recalcitrant disease. In this review, we discuss recent discoveries concerning
dysregulated microRNA (miR) expression and putative pathological roles of oncogenic and tumor
suppressive miRs in CTCL. We also focus on the interplay between miRs, histone deacetylase
inhibitors, and oncogenic signaling pathways in malignant T cells as well as the impact of miRs
in shaping the inflammatory tumor microenvironment. We highlight the potential use of miRs as
diagnostic and prognostic markers, as well as their potential as therapeutic targets. Finally, we propose
that the combined use of miR-modulating compounds with epigenetic drugs may provide a novel
avenue for boosting the clinical efficacy of existing anti-cancer therapies in CTCL.
Keywords: microRNA; miR; cutaneous T-cell lymphoma; CTCL; mycosis fungoides; cancer; tumor
suppressor; oncogene; biomarker; targeted therapy
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1. Introduction
1.1. Etiology of Cutaneous T Cell Lymphoma
Cutaneous T-cell lymphoma (CTCL) comprises a heterogeneous group of non-Hodgkin
lymphomas characterized by the proliferation of neoplastic T cells in a chronic inflammatory
environment. CTCL can be divided into subgroups, with mycosis fungoides (MF) being the most
prevalent form, and in most cases a relatively indolent cancer (Figure 1). Sézary syndrome (SS) is a rare,
highly aggressive leukemic variant of CTCL and is associated with extensive exfoliative erythroderma
(Figure 1) [1]. Early stage MF presents with patches and plaques and some patients may progress to
advanced stages, presenting with cutaneous tumors and/or malignant T cell dissemination to lymph
nodes, blood and visceral organs (Figure 1). MF lesions are frequently large, multifocal and highly
pruritic; however, a broad range of MF variants have been described (e.g., folliculotropic, pagetoid
reticulosis, hyperpigmented, granulomatous, granulomatous slack skin, poikiloderma vasculare
atrophicans, unilesional and erythrodermic MF) [1,2]. Early diagnosis of CTCL (in particular MF)
is difficult due to resemblance of CTCL with benign skin inflammatory dermatoses. Indeed, it may
take up to 5 years and multiple skin biopsies to obtain a definitive diagnosis [1,2]. Moreover, it is
generally impossible to predict which patients will suffer from an aggressive clinical course [3]. Despite
intense research efforts in recent years, the pathogenesis of CTCL still remains poorly understood.
Genetic, epigenetic, and environmental factors have all been proposed to be implicated in CTCL [1,4,5].
To date, no studies have identified overarching mutational drivers explaining the pathogenesis of
this cancer; however, genetic aberrations may be important in a subset of patients, but are not
sufficient to explain the full complexity of CTCL’s pathology [6]. Abnormalities of certain molecular
pathways are frequently observed in CTCL and are believed to play an important role in a subset of
patients [7]. Recurrent mutations include genetic abnormalities that facilitate constitutive activation of
JAK/STAT signaling as well as oncogenic mutations that potentiate constitutive NFkB signaling [8–13].
Recently, several lines of evidence have pointed towards a key role for epigenetic dysregulation in the
pathogenesis of CTCL [14–16]. This is a notion further highlighted by the efficacy of therapeutic drugs
targeting the genome’s epigenetic landscape (e.g., histone deacetylase (HDAC) inhibitors romidepsin
and vorinostat) [17,18].
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small, endogenous single-stranded 20–25 nucleotide RNA molecules and are one of the best
characterized groups of ncRNAs [19]. miR biogenesis initiates with the transcription of miR genes,
after which the primary miR transcripts are cleaved by enzymes including Drosha and then further
processed by the ribonuclease Dicer to produce the mature and functioning miR form [20]. miRs have
emerged as key post-transcriptional regulators, causing translational inhibition or degradation of
mRNA by binding to the 3′ untranslated region of their target-mRNA, thereby fine-tuning protein
expression [21]. miRs regulate at least 30% of human genes and play key roles in various aspects
of normal cellular processes, including cell proliferation, differentiation, apoptosis and immune
responses [19,21]. The role of dysregulated miRs has been elucidated in numerous types of inflammatory
skin disorders and cancers. Notably, half of the miR-encoding loci are tumor-associated or located in
fragile loci and were proposed to have modulatory effects on tumorigenesis [19,22]. Some miRs act as
oncogenic miRs (oncomiRs), driving mechanisms that contribute to carcinogenesis, whereas others act
as tumor suppressors. Interestingly, some miRs can have a dual role, depending on the context and the
tissue where they are being expressed [19].
A large number of findings highlight the importance of investigating the role of aberrantly
expressed miRs in CTCL pathogenesis and exploring their use in disease diagnosis and prognosis.
2. Differentially Expressed miRs in CTCL
miR profiles have been extensively studied, and a large number of studies have reported on
dysregulated miR expression in CTCL. miR-155 was among the first to be identified as being aberrantly
overexpressed in this cancer and numerous studies have since highlighted miR-155 as a key player in
oncogenesis [23–27]. Hundreds of miRs have been reported to be differentially expressed in patients
diagnosed with tumor stage MF compared to controls. These include the upregulation of miR-93,
miR-155, miR-181, miR-142 and downregulation of miR-200c, miR-203 and miR-205 [24,26,28]. In SS
cohorts, miR-21, miR-181 and miR-214 were identified as highly expressed miRs, whereas miR-150 was
shown to be downregulated [29–32]. Striking differences as well as similarities in miR patterns have
been reported between CTCL variants [25,27,33]. Of particular interest, tumor stage MF and SS showed
only few overlaps among differentially expressed miRs. Surprisingly, some miRs, such as miR-93 and
members of the miR-17/92 cluster, were upregulated in tumor stage MF, but reduced in SS [27,31].
Likewise, a study comparing miR profiles in erythrodermic MF and SS (that are often clinically and
histopathologically difficult to distinguish) demonstrated that erythrodermic MF is characterized by a
miR expression profile resembling that of early MF rather than that of SS, thus underscoring that these
are two distinct disease entities [33].
3. Dysregulation of miRs in CTCL
Dysregulated miRs are likely involved in disrupting normal cellular processes related to
carcinogenesis in CTCL. The putative mechanisms leading to the dysregulation of miRs in CTCL
have not been fully elucidated and several mechanisms may promote and/or inhibit the expression
of miRs. Aberrant DNA methylation patterns of miR promoters were reported in CTCL [34].
Accordingly, miR-200c appears to be epigenetically silenced by promoter methylation in CTCL,
contributing to enhanced activation of Notch signaling, associated with CTCL carcinogenesis [35,36].
Genomic analysis has revealed that DNA copy number variations in miR encoding genes may also
contribute to aberrant expression of some miRs including high expression of miR-93, which facilitate
sustained proliferation [27,37,38]. Furthermore, there are strong indications that abnormal regulation
of transcription factors, including the constitutive activation of STAT signaling, drives the enhanced
expression of miRs e.g., miR-155 and miR-21. These miRs are believed to promote oncogenesis through
direct effects on proliferation/apoptosis in malignant T cells and indirectly by modulating the tumor
microenvironment [39–41]. Simultaneously, aberrant STAT activation also seems to repress expression of
tumor suppressor miRs, e.g., miR-22, further contributing to oncogenesis [42]. Moreover, dysregulation
of the enzymes Dicer and Drosha, involved in miR biogenesis and processing, was reported in several
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cancers, resulting in defective processing and thus altered miR profiles in cancers [20]. Interestingly,
increased expression of Dicer and reduced expression of Drosha was observed in CTCL, reflecting the
complexity of miR dysregulation, which remains to be further understood [43,44].
A comprehensive study, taking advantage of the Danish cohort of twins, suggested that CTCL
has very few heritable components, and several lines of evidence indicate that environmental factors
may play a promoting or even initiating role in the carcinogenesis of CTCL [5,45]. Accordingly, it may
be speculated that exogeneous factors including drugs, pesticides, and bacterial toxins may promote
disease progression [5]. Indeed, in a recent study, Lindahl et al. [46] reported that aggressive antibiotic
therapy inhibited skin colonization by toxin-producing Staphylococcus aureus (Staph A), decreased
disease activity as well as the fraction of malignant T cells present in lesional skin in patients with
advanced CTCL. These results suggest that bacteria may fuel disease activity [46]. Likewise, Staph
A-derived toxins appear to tilt the balance between malignant and non-malignant infiltrative CD4+ T
cells in the favor of enhanced survival of malignant T cells [47]. In support of a microbial driver of
CTCL activity, Fanok et al. [48] demonstrated in a murine model of CTCL that disease progression is
dependent on microbiota [48]. Of note, Willerslev-Olsen et al. documented that Staph A’s enterotoxins
induce STAT5-mediated expression in malignant T cells obtained from SS patients [49]. As STAT5
activation was previously shown to trigger miR-155 expression and Staph A-derived enterotoxins
induce miR-155 in T cells, it is likely that Staph A and its toxin trigger miR-155 in CTCL skin lesion
in vivo [40,50]. Interestingly, Helicobacter pylori (H. pylori) and its cytotoxin-associated gene A (CagA)
were shown to promote malignant transformation of gastic mucosal epithelial cells. H. pylori impairs
DNA mismatch repair and facilitates tumor growth through the induction of miR-155, suggesting that
H. pylori, at least partly, mediates carcinogenesis through miR-155 expression in gastric cancer [51,52].
Additionally, H. pylori has been reported to promote carcinogenesis via miR-155 upregulation in a
model of gastric mucosa-associated lymphoid tissue (MALT) lymphoma [53]. Further studies are
warranted to address the putative link between environmental factors such as Staph A, deregulated
miR expression, and CTCL disease activity.
4. OncomiRs in CTCL Pathogenesis
Emerging evidence indicates that miRs are involved in the pathogenesis of CTCL. miR-155,
miR-214 and miR-21 are to date the best established oncomiRs that drive carcinogenesis.
4.1. Role of miR-21 in Malignant Proliferation
miR-21 is abundantly expressed in various tumors. Notably, it is upregulated in malignant T cells
both in the tumor microenvironment of MF and in circulating cells isolated from SS patients [29,34,54].
Through chromatin immunoprecipitation (ChIP) analysis, it was found that elevated miR-21 expression
is driven directly by transcription factors STAT3 and STAT5 [39,41]. Thus, activating mutations of
these or cytokine-induced activation of STAT signaling promote high expression of miR-21. Several
studies on SS patients indicated that abundant expression of miR-21 contributes to apoptotic resistance
in CTCL [29]. Accordingly, miR-21 was able to promote cell survival in SS cells, and silencing of
miR-21 in malignant T cells induced apoptosis [41]. The status of PTEN, a well-established tumor
suppressor, is frequently downregulated in neoplastic cells, and miRs including miR-21 and miR-106b
were suggested to play a role in reducing the expression of PTEN [55,56].
4.2. Role of miR-155 in Disease Progression
The role of miR-155 is well-established in oncology, and the consequences of aberrant expression
of miR-155 have also been addressed in relation to CTCL. Several reports indicate that miR-155 is
important in promoting proliferation and tumor progression. Kopp et al. provided the first evidence
that both malignant T cells and non-malignant T cells express miR-155 in CTCL lesions in situ [57].
Additionally, miR-155 was shown to be significantly upregulated in lymphoma cells in tumor stages
compared to lymphocytes in early stages [58]. Functionally, miR-155 targets the global chromatin
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organizer and transcription factor, Special AT-rich sequence-Binding protein 1 (SATB1) [59]. Thus, SATB1
inhibition by miR-155 in malignant T cells promotes proliferation and induces the expression of
the Th2 cytokines IL-5 and IL-9, which are involved in CTCL pathogenesis as growth factors and
inflammatory mediators [59,60]. The oncogenic role of miR-155 in CTCL is further supported by
findings in an xenograft mouse model of CTCL, where treatment with a miR-155 inhibitor triggered
enhanced apoptosis in malignant T cells [61].
Notably, in relation to STAT signaling in CTCL, it should be noted that aberrant STAT5 activation
enhances the expression of the miR-155 host geneBIC (B-cell integration cluster) and miR-155, facilitating
proliferation in malignant T cells [40]. In contrast, reports have revealed that the transcription factor
STAT4, critical for Th1 phenotype differentiation, is downregulated in CTCL [62]. Loss of STAT4 is
associated with the switch towards a Th2 inflammatory environment, subsequently orchestrating
a tumor-promoting inflammatory state [63]. Interestingly, siRNA-mediated miR-155 knockdown
enhanced STAT4 expression in malignant T cells, indicating that deficient STAT4 expression is, at least
partly, driven by miR-155 [63]. Thus, miR-155 may also play a key role in the switch from Th1- to the
Th2-dominant environment frequently observed in MF skin lesions during disease progression [62].
In addition to repressing SATB1 and STAT4 in CTCL, miR-155 regulates multiple signaling
pathways of potential importance in malignant transformation. For instance, miR-155 targets several
genes encoding tumor suppressors and inducers of apoptosis in other cancers (Table 1) [64]. To address
whether miR-155 also represses these tumor suppressors in CTCL, we treated malignant T cells with
anti-miR-155 and a non-targeting control prior to the analysis of changes in mRNA expression as
previously described [59]. Interestingly, a series of well-established miR-155 targets such as PDCD4,
JARID2, ARID2, ZNF652, and SMAD5 displayed a ≥2-fold upregulation in malignant T cells following
miR-155 inhibition (Table 1, right column, unpublished data). Thus, miR-155 may promote malignant
transformation and disease progression of CTCL by the inhibition of multiple tumor suppressors and
pro-apoptotic pathways in CTCL (Figure 2). Moreover, the literature indicates that miR-155 has several
direct and indirect downstream targets that affect essential survival pathways such as JAK/STAT,
PI3K-AKT, p38-MAPK [65].
Table 1. Putative miR-155 targets in CTCL.
miR-155 Targets Role in Cancers ValidatedFunctions Fold Change References
JARID2 Tumor suppressor in leukemia
Reduces
proliferation and
survival
2.2 [66–69]
PDCD4
Tumor suppressor in leukemia,
tongue-, colorectal- and
cervical cancer, mutated in SS
Increases apoptosis
Induces cell cycle
arrest
2.0 [70–74]
ZNF652 Tumor suppressor in breastcancer
Represses drivers
of invasion and
metastasis
3.4 [75,76]
SMAD5 Tumor suppressor in leukemiaand B-cell lymphoma
Plays a role in
growth inhibition
of malignant cells
2.2 [77–79]
ARID2
Tumor suppressor in
hepatocellular carcinoma and
oral cancer, mutated in SS
Suppresses growth
and progression of
tumor cells
2.1 [64,80,81]
Table 1 The malignant T cell line MF2059, established from an MF patient, was treated with anti-miR-155 and a
non-targeting control prior to the analysis of changes in mRNA expression, as previously described [59].
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4.3. Role of miR-214 in Promoting Cell Survival in SS
The human miR-214 gene is located in an intron of the DN 3 gene. DN 3 is known to be
overexpressed in SS and the gene is regulated by SS-associated transcription factors including TWIST1,
potentially accounting for the abundant expression of miR-214 in SS [29,30,82]. In contrast to miR-21,
miR-214 is predominantly overexpressed in circulating malignant T cells [82]. Addressing the functional
role of miR-214 revealed that miR-214 promotes cell survival in malignant SS cells, thus facilitating
apoptosis resistance in CTCL [29]. Furthermore, the inhibition of miR-214 was shown to decrease
disease severity in a CTCL disease mouse model [83].
4.4. The miR-17/92 Cluster—Role as oncomiRs or Tumor Suppressor miRs in CTCL?
Members of the miR cluster miR-17/92 have been proposed to act as both tumor suppressors and
oncomiRs in cancers depending on the cellular context [84]. In CTCL, several studies have addressed
the expression of this miR cluster. Downregulation of the miR-17/92 cluster was observed in SS T cells
compared to healthy controls. Moreover, ectopic overexpression of miR-17-5p in SS T cells improved
the proliferative ability concomitant with increased apoptosis in these cells [31]. Notably, another study
reported that the expression of miR-17-3p was increased in SS T cells compared to healthy controls [29].
In advanced MF lesions, the expression of this cluster was found to be upregulated compared to
early MF stages or benign inflammatory dermatoses [27,54]. Interestingly, different levels of the miR
cluster were associated with different types of MF. Abundant expression of the miR-17/92 members
was reported in unilesional MF, exhibiting a less aggressive type compared to MF multifocal early
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disease. Furthermore, increased levels of the miR-17/92 cluster members correlated with a Th1-skewed
cytokine microenvironment [85]. Thus, the expression of miR-17/92 was suggested to contribute to a
robust reactive T cell immune response, likely to explain the less aggressive disease phenotype [85].
Taken together, discrepancies regarding the role of the miR-17/92 cluster exist in CTCL, and differences
in miR expression levels in different cell types and cellular settings may explain these inconsistencies.
5. Key Tumor Suppressive miRs Playing a Role in CTCL Pathogenesis
Overcoming apoptosis and senescence while sustaining proliferation and promoting invasion
are hallmarks of cancer [86]. In addition to driving tumorigenesis, miRs may also exhibit
tumor-suppressive properties, and the repression of such miRs may result in the progression of
cancer. Studies identifying miRs as tumor suppressors in CTCL have revealed that miR-337 is
substantially downregulated in malignant T cell lines suggestive of its tumor suppressive role. Indeed,
ectopic overexpression of miR-337 suppressed key aspects of CTCL such as viability and invasion.
The tumor-suppressive properties were induced through direct repression of STAT3 activity, essential
for CTCL tumorigenesis [11,87]. Other findings suggest that miR-150 is an important player in CTCL
tumor invasion. miR-150 shapes the inflammatory tumor microenvironment of advanced CTCL by
repressing the autocrine IL-22-CCL20-CCR6 signaling [88]. Consequently, diminished expression of
miR-150 induces CCR6 chemotaxis, subsequently facilitating the migrative potential of CTCL cells [88].
Furthermore, miR-16 has been shown to be significantly downregulated in advanced disease [89].
Notably, forced expression of miR-16 induced expression of the cell cycle regulator p21, leading to cell
cycle arrest [89,90].
In addition, other miRs may play a role in CTCL, including miR-22, miR-135a and miR-223.
Diminished expression of miR-135a, miR-223 and miR-22 may allow for the high expression of critical
transcription factors including GATA3 as well as growth and proto-oncogenes such as E2F1 and c-Myc,
respectively, collectively contributing to CTCL pathogenesis and progression [42,91,92].
6. Non-Canonical Functions of miRs
Chronic itch is a major symptom in patients suffering from CTCL. For years, it remained unknown
which mediators may be involved in causing it. Some lines of evidence suggested IL-31 as an important
driver of pruritus. However, this notion is still controversial, as other studies did not observe an
association between Il-31 and severe itch in CTCL patients [93–95]. Recently, Han et al. demonstrated
that miR-711, which is highly expressed in CTCL, promotes itching through an unconventional
signaling mechanism, as miR-711 was shown to evoke itching by binding extracellularly to the ion
channel TRPA1 on sensory neurons [96].
Additionally, miRs can act as physiological ligands for specific Toll like receptors (TLRs) and
initiate signaling cascades of immune responses [97,98]. Interestingly, miRs known to be upregulated
in CTCL, such as miR-21 and several let-7 family members, have been demonstrated to serve as
ligands for TLRs in different cells types, modulating complex mechanistic networks [54,98,99]. Thus,
unconventional miR signaling may be of future therapeutic interest for CTCL.
An overview of the miRs known to play a role in CTCL pathogenesis is summarized in Table 2.
Table 2. Roles of miRs in CTCL pathogenesis.
MicroRNA Status in CTCL Validated Functions
miR-16 Downregulated in CTCLUpregulated by HDAC inhibition Increases p21 and cell cycle arrest
miR-17/92 Upregulated in tumor MFReduced in SS
Influences cytokines in MF
Tumor suppressive properties in SS
miR-21 Upregulated in CTCLDriven by STAT signaling
Targets PTEN
Increases cell survival
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Table 2. Cont.
MicroRNA Status in CTCL Validated Functions
miR-22 Downregulated in CTCLRepressed by STAT signaling Suppresses c-Myc
miR-29b Downregulated in CTCLReduced by IL-15 Suppresses BRD4
miR-93 Upregulated in tumor MFReduced in SS
Represses p21 expression
Induces proliferation in MF
miR-122 Upregulated in CTCL Decreases sensitivity to chemotherapy
miR-125b OncomiR in CTCLRegulated by c-Myc Represses sensitivity to Bortezomib
miR-135a Downregulated in CTCL Suppresses GATA3
miR-150 Downregulated in advanced CTCLUpregulated by HDAC inhibition
Shapes the inflammatory environment
Inhibits migration
miR-155 Upregulated in CTCLDriven by STAT signaling
Increases proliferation and survival
Targets multiple pathways
miR-200c Downregulated in CTCLSilenced by promotor methylation Inhibits Notch signaling
miR-214 Upregulated in SSDriven by TWIST1 and BRD4
Promotes cell survival
Increases disease severity in mouse models
miR-223 Downregulated in CTCL Suppresses E2F1Reduces cell growth
miR-337 Downregulated in CTCL Targets STAT3 signalingInhibits cell viability
miR-711 Upregulated in CTCL Causes pruritus
7. miRs as Diagnostic, Prognostic and Treatment Predictive Biomarkers
In clinical practice, MF and SS remain challenging to diagnose and distinguish from benign
inflammatory skin disorders [1]. The median time from initial appearance of skin lesions to the
diagnosis of MF cases is around 4 years [1]. Notably, delays in diagnosis have been found to exceed
four decades in some patients [1]. As discussed above, there is increasing evidence that skin diseases
and certain cancers demonstrate unique miR profiles. Thus, aberrant miR expression signatures may
help to diagnose and prognosticate CTCL. To date, a number of clinical trials are actively testing the
value of using miRs as biomarkers or have already been completed [100].
Early MF disease often follows an indolent course, but some patients progress to more advanced
stages rapidly. It would be an advantage in MF management to be able to predict patients at high risk
of developing the aggressive disease [1,3]. Furthermore, it could be hypothesized that earlier initiation
of systemic treatments and enhanced clinical monitoring may increase overall life expectancy in these
patients. This could also apply to patients diagnosed with the aggressive CTCL variant SS, that in
general has poor prognosis, and where early diagnosis potentially would be important to achieve
enhanced therapeutic response.
In 2011, the first diagnostic miR profile able to differentiate between MF and benign skin
inflammatory disorders was published. The profile includes a decreased expression of miR-203 and
miR-205 and increased expression of miR-155 [101]. The study was confirmed in an independent
cohort of patients [102], and subsequently, Ralfkiaer et al. reported that early MF and atopic dermatitis
display very different miR patterns, including different levels of miR-203, miR-205 and miR-155 [54].
Accordingly, a long list of dysregulated miRs were identified, including miR-181 and miR-146a [54].
Numerous miRs were further identified as being associated with a progressive disease. Notably,
miRs such as miR-93, miR-106b and miR-181 are found to be associated with advanced stages of MF,
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suggesting a possible role in malignant transformation and progression [54]. Other investigations
have suggested that a minimal classifier of just four miRs (miR-181a, miR-146a, miR-222, miR-26a)
could discriminate tumor stage MF from benign conditions [28]. Interestingly, two of these miRs
(miR-181a, miR-146a) were proposed to be involved in the progression from early MF to advanced
disease (stage >IIB) [54,103]. Of notice, a recent study examining a cohort of Chinese CTCL patients
validated the relevance of the aforementioned diagnostic classifiers [28]. Inclusion of miR-130b,
miR-142-3p, miR-200c appeared to further strengthen the diagnostic potential. However, miR-205 did
not contribute to the diagnostic strengths and accuracy of the classifier in this study, potentially due to
ethnic differences in the cohorts. This highlights the importance of validating miR classifiers in cohorts
of different ethnic backgrounds [28]. The discovery of circulating miRs in human plasma sparked
intensive research, as these could serve as accessible and hence convenient biomarkers. miRs may
be detected in the blood as a result of the passive leakage of cells including tumor cells, or they can
be present in cell-secreted exosomes. Circulating miRs in the blood are very stable and not easily
degraded, thus possessing the ability to be applied for clinical monitoring [104]. In CTCL, the 3-miR
classifier (miR-203, miR-205, miR-155) was evaluated in a study investigating plasma levels of miRs
and proposed that screening plasma levels for these molecules could be a valuable tool for diagnosis
and monitoring the disease activity and progression in CTCL [104].
In addition to using miR profiling as a diagnostic tool in CTCL, miR profiling also emerged as a
potentially important prognostic tool. This is of key clinical importance, as it is notoriously difficult to
predict which patients are at risk of disease progression and, therefore, are in need of special attention
and aggressive therapy. This is supported by the fact that non-progressive disease usually takes an
indolent course with a good prognosis and an almost normal life expectancy, while patients with
progressive disease often only display partial or transient responses to treatments and have a poor
prognosis [1]. To investigate the potential use of miR profiling for disease prognostication, Lindahl
et al. [3] investigated a large cohort of early MF patients with the goal to identify and validate a
prognostic miR classifier. This miR classifier, consisting of miR-106b-5p, miR-148a-3p and miR-338-3p,
successfully predicted patients at high risk of a progressive disease course and with reduced overall
survival [3].
Moreover, miR profiles may also predict the response to therapy. Specifically, a recent study
reported that MF patients who had a rapid increase in miR-223, miR-191 and miR-342 levels following
extracorporeal photopheresis were more likely to demonstrate a favorable clinical response after
6–12 months [105]. Furthermore, a number of reports demonstrated that miRs may determine the
response to cancer therapy, which is often hampered by therapeutic resistance and presents a major
clinical challenge. For instance, the c-Myc/mirR-125b signaling pathway was shown to regulate
the sensitivity of tumor cells toward the proteasome inhibitor bortezomib in a pre-clinical model of
CTCL. According to the study, high expression of miR-125b increased cellular resistance and tumor
growth [106]. Moreover, upregulation of another miR, miR-122, was shown to act as an amplifier in an
antiapoptotic signaling circuit, decreasing the sensitivity in CTCL to chemotherapy [107]. A predictive
biomarker may not only reduce valuable time spent on futile and toxic therapies but may also help in
tailoring the optimal treatment for individual patients.
Taken together, emerging evidence suggests an important clinical potential of miRs as biomarkers in
CTCL (Figure 3). Prognostic and treatment predictive miR profiles may pave the way for implementation
of personalized medicine in these patients. Several of the miRs that were reported to play a key role as
biomarkers in CTCL also have a functional impact in CTCL pathology, therefore potentially serving as
relevant targets for future therapies. Larger studies are still highly warranted to fully establish miRs as
diagnostic, prognostic and predictive classifiers in CTCL.
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Figure 3. miRs as diagnostic, prognostic and predictive biomarkers. miRs possess an important clinical
potential to be used as biomarkers. In CTCL, evidence suggests that they may be able to discern CTCL
from benign inflammatory dermatoses (diagnosis) as well as distinguish between subtypes of CTCL
(distinguishing CTCL variants). Furthermore, miRs may be able to stratify patients into low vs. high
risk of progression groups (risk of progression) and could be used to monitor progression in patients
(monitoring progression). Additionally, expression of certain miRs may be able to predict treatment
outcomes (therapeutic outcomes).
8. Dual Interplay between miRs and Therapeutics Targeting the Epigenome
Alterations in th epigenome are known to be present in a variety of diseases, and emergi
insights suggest that epig netic modifiers ar promising targets in cancer therapy [1]. HDAC inhibitors
are clinically approved f r the treatment of CTCL and have already been proven effective in everyday
clinical practice [1,17]. Several r ports have investigated the rol of HDAC inhibitors in modulating the
miR vironment in CTCL. Importantly, the HDAC i hibitor vorinostat re tored epigenetic silencing
of tumor suppressive miRs including miR-16, miR-22 and miR-150 leading to increased apoptosis in
CTCL as well as attenuating the migrative potential of CTCL cells [42,89,108]. Epigenetic regulation
also seems to be of pivotal importance in reverting the high expression of miRs, including miR-93,
as its expression is reduced by vorinostat treatment [38].
Excessive expression of cytokines including IL-15 has been implicated in CTCL pathogenesis [109].
Autocrine IL-15 signaling drives induction of several HDACs along with an increased expression of
oncomiR-21 [110]. Moreover, IL-15 has been shown to promote reduction in the expression level of
miR-29b, which is involved in regulating bromodomain-containing protein 4 (BRD4), an epigenetic
reader protein that contributes to the modulation of the epigenetic landscape by recognizing and binding
to epigenetic modifications [111]. The oncogenic activity of BRD4 was inhibited by restoring the miR-29b
activity by bortezomib treatment or directly by a bromodomain inhibitor (JQ1), both interventions
leading to the prevention of disease progression in CTCL [111].
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9. miR Targeted Therapy
Based on the discussed literature, it is evident that miR-targeting drugs possess the potential
to restore homeostasis of multiple oncogenic networks in CTCL. Indeed, preclinical validations of
numerous miR drug candidates have been reported and early active phase trials of miR are currently
being performed; however, phase 3 trials targeting miRs still remain to be initiated [83,100,112].
As a consequence of the ever expanding body of evidence highlighting the implication of miR-155
in CTCL pathogenesis, cobomarsen (MRG-106), an oligonucleotide inhibitor of miR-155 was recently
developed [65]. It is anticipated that the inhibition of miR-155 will reverse the malignant phenotype of
malignant T cells, preventing the oncogene network from facilitating a constitutive survival loop in
CTCL. In a preclinical study, it was observed that cobomarsen inhibits cell proliferation and induces
apoptosis in CTCL cells. Moreover, cobomarsen reduces the activation of oncogenic signaling pathways
such as the JAK/STAT and PI3K/AKT (Figure 2) [65]. Its proliferative inhibition was comparable to the
effects observed by treating with bexarotene, a commonly prescribed rexinoid medication in CTCL [65].
Phase 1 trials were encouraging as they reported cobomarsen to be well tolerated with signs of a
favorable clinical activity [112,113]. Studies are currently recruiting patients for phase 2 clinical trials
in CTCL [112,113]. Given the dual interplay between miR-155 and JAK/STAT with STAT5 inducing
transcription of the miR-155 host gene and miR-155 promoting JAK/STAT signaling, it is tempting to
speculate that combined targeting of both miR-155 and JAK/STAT5 may act in synergism. In support,
JAK/STAT is believed to also promote oncogenesis in a miR-155-independent manner [42,114,115].
On the other hand, miR-155 expression can also be induced in a STAT-independent fashion relying
on other transcription factors, potentially NFkB [65,116]. Other miR targeted therapies may also
exhibit clinical utility for the treatment of CTCL. Of particular interest are inhibitors targeting miR-214
and miR-21 or miR mimics restoring tumor suppressor miRs. Preclinical studies demonstrated that
antagomiR-214 treatment significantly decreased disease severity in a CTCL mouse model, and miR-21
seems to be highly involved in promoting malignant growth [83]. Thus, continued efforts to uncover
which miRs possess potential as therapeutic targets are still warranted [100].
10. Conclusions
Accumulating evidence suggests that aberrant expression of numerous miRs participates in
driving oncogenic survival pathways and disease progression in CTCL. Efforts to further elucidate
and validate the diagnostic, prognostic and predictive miR classifiers may pave the way for both
earlier diagnosis, improved monitoring, risk-assessment of disease progression, predicting treatment
outcomes and eventually enabling us to implement personalized medicine. Moreover, miR targeting
therapies alone or in combination with epigenetic drugs may provide a novel avenue for improving
the clinical efficacy of treatments for CTCL patients.
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